Introduction
Defects in cellular differentiation and apoptosis are a common occurrence in leukemias. The ability of the cells to exit the cell cycle, induce apoptosis, and differentiate is mediated by intricate molecular and biochemical mechanisms. A deeper understanding of the factors controlling terminal differentiation and drug-induced apoptosis of leukemic cells should allow the development of therapeutic strategies. 1 Protooncogenes have been implicated in the regulation of both cellular differentiation and apoptosis. 2 For example, enhanced expression of c-myc inhibits the terminal differentiation of leukemic cells. 3 In contrast, c-myc can increase apoptosis of leukemic cells under certain conditions. 4 C-jun is another potential candidate for a gene which can influence differentiation and apoptosis.
The proto-oncogene c-Jun belongs to the bZIP group of DNA binding proteins and is a component of AP-1 transcription factor complexes. 5, 6 C-Jun forms homodimers or can heterodimerize with other Jun family members or with other bZip proteins of the Fos, ATF/CREB, and, more recently, Maf families. 7 C-Jun has been shown to be involved in many cellular processes including proliferation, differentiation, apoptosis, and stress responses. [8] [9] [10] While the proto-oncogene c-Jun has been implicated as a positive regulator of cell proliferation and G1-to S-phase progression, 11 it is also known to play a key role in biological processes other than proliferation. In particular, it may regulate the differentiation of many different lineages such as myeloid, [12] [13] [14] erythroid, 15, 16 epithelial, 17 and neuronal cells. 18 The involvement of c-Jun in the differentiation of leukemic cells is complex. There is evidence that c-Jun plays a role in monocyte/macrophage differentiation. C-Jun is up-regulated upon the monocytic differentiation of U937 and HL-60 leukemia cells 19 while stable transfection of c-Jun into U937 and WEHI-3 leukemia cells results in partial monocytic differentiation. 14, 20 In contrast, c-Jun is not involved in the granulocytic differentiation of HL60 cells. C-Jun is also induced upon megakaryoblastic differentiation of K562 leukemia cells, 21 but is not induced during erythroid differentiation of these cells. 22 Moreover, c-Jun inhibits chemically-induced erythroid differentiation of murine erythroleukemia (MEL) cells. 15 Since c-Jun is a positive regulator of proliferation it would be interesting to know whether it might regulate the terminal maturation of leukemic cells with total cessation of growth. Transfection of c-Jun in U937 cells is not sufficient to cause terminal differentiation but accelerates that of TPA-induced terminal differentiation. 20 However, the involvment of c-Jun in the terminal differentiation of other leukemic cells remains unknown.
In addition, c-Jun is involved in the control of apoptosis. 9, 10, 23 Recently, c-Jun has been linked to the induction of apoptosis under certain conditions, for example, in the case of factor-deprived fibroblasts, 24 neuronal apoptosis upon withdrawal of survival factors, 25 bufalin-induced apoptosis in U937 cells, 26 and vitamin E-induced apoptosis in lymphoid cells. 27 Moreover, c-jun N-terminal kinase (JNK), which phosphorylates the transactivation domain of c-Jun, 28 has been shown to be involved in apoptosis. 29, 30 However, it should be noted that c-Jun may provide protection against apoptosis under certain conditions such as exposure to UV or ionizing irradiation. 31, 32 These results suggest that the proto-oncogene c-Jun may function to modulate stress-induced apoptosis either positively or negatively, depending on the microenvironment and the cell type. The involvement of c-Jun in apoptosis of leukemic cells is unclear. C-Jun is up-regulated in human leukemia cells exposed to different anticancer agents inducing apoptosis, such as etoposide or Ara-C. 33, 34 It is also reported that the activation of c-Jun is necessary to ceramideand heat shock-induced apoptosis in HL-60 cells. 35, 36 MEL cells have been the subject of extensive studies as one of the best models for terminal differentiation. Upon exposure to inducing agents (DMSO or HMBA), MEL cells are converted to cells that exhibit all the characteristics of erythroid cells, including the loss of growth proficiency. 37 Terminal differentiation of MEL cells is evidenced by inhibition of cell proliferation and induction of hemoglobin synthesis. 38, 39 We have previously shown that c-Jun is a negative regulator of hemoglobin synthesis in DMSO-induced MEL cells, 15 but it is not known whether c-Jun affects the differentiation program concerned with a loss of proliferative capacity. Moreover, MEL cells are sensitive to different anticancer drugs. 40 Therefore, MEL cells provide a useful system to study the involvement of c-Jun in terminal differentiation and apoptosis. In the present work, we made use of different stable transfectant MEL clones containing c-jun constructs in sense or antisense orientation. We found that c-Jun does not prevent the growth arrest that is normally associated with terminal differentiation, and increases drug-induced apoptosis in MEL cells.
Materials and methods

Chemicals, antibodies and GST-c-jun
Anisomycin (Sigma, St Louis, MO, USA) was diluted in ethanol to a concentration of 25 mg/ml and stored in the dark for 1 month at 4°C. Daunorubicin (Sigma) was diluted in water to a concentration of 10 mM and stored at 4°C for 6 months. VP-16 (Sigma) was diluted in DMSO to a concentration of 5 mg/ml and stored at −20°C.
The primary antibodies used in Western blots were mouse monoclonal anti-c-jun/AP-1 from Transduction Laboratories (Lexington, MA, USA); rabbit polyclonal anti-phospho-c-jun (Ser63) from New England Biolabs (Beverly, MA, USA); rabbit polyclonal anti-p21 from Santa Cruz Biotechnologies (Santa Cruz, CA, USA); and rabbit polyclonal anti-PARP from PharMingen (San Diego, CA, USA). The GST-c-jun (1-89) fusion protein beads were purchased from New England Biolabs.
Cell lines
F-MEL cells, strain 745A and TFP10 and derived transfectants were grown in RPMI-1640 medium (Gibco-BRL, Cergy Pontoise, France) containing 10% fetal calf serum (FCS, Eurobio, Les Ulis, France). 41 C-jun sense 745A clones and c-jun antisense TFP10 clones have been previously described. 15 Cells were suspended in fresh medium at a cell density of 1 × 10 5 cells/ml every 2 days. The number of cells and the percentage of cell viability were estimated by the trypan blue dye exclusion test. Cells were routinely examined for mycoplasma contamination.
Cell cycle analysis
Cell cycle distribution was assessed by flow cytometry. After centrifugation of cells, pellets were resuspended in a hypotonic propidium iodide (PI) solution containing 25 g/ml PI, 0.1% trisodium citrate dihydrate, and 0.1% v/v Triton X-100 in distilled water, and a 10% v/v RNAse solution (1 mg/ml in PBS with 0.5 mM EDTA). Cells were kept on ice for 20-24 h and subsequently analyzed for DNA staining. Nuclear fluorescence was measured by quantitative flow cytometry and profiles were generated on a FacsCalibur analyzer (Becton Dickinson, Le Pont de Claix, France).
Western blot analysis
Cells were washed twice in PBS, resuspended gently in lysis buffer containing 25 mM Tris HCl pH 7.5, 10 mM EDTA, 50 mM NaF, 150 mM NaCl, 1 mM sodium orthovanadate, 1% NP-40, plus protease inhibitors, 15 and then incubated for 1 h at 4°C. The lysate was centrifuged for 15 min at 10 000 g and total protein concentration in the supernatant was determined by the Micro BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). For each extract, 30-50 g of total cellular protein were resolved by 8 or 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were transferred to PolyScreen membranes (NEN, Le Blanc Mesnil, France). Non-specific binding was reduced by pretreating the membrane overnight at 4°C with 5% unfatted milk in TBS/0.05% Tween 20 (TBS-T). Membranes were then incubated for 1 h at room temperature with primary antibodies in TBS-T. Subsequently, membranes were incubated with anti-mouse (1:5000; Immunotech, Marseille, France) or anti-rabbit (1:25 000; Transduction Laboratories) antibody conjugated with horseradish peroxidase (HRP) for 1 h at room temperature. All steps were followed by two washes for 15 min in TBS-T. The protein bands were detected as described in the ECL protocol (NEN) using Reflection autoradiography film.
JNK kinase assay
Samples containing 2 × 10 7 cells (unstimulated or stimulated with anisomycin or daunorubicin) were washed in ice-cold PBS and resuspended in 500 l of ice-cold JNK lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 1 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin and 10 M pepstatin). Pellets were vortexed and incubated on ice for 5 min three times. Lysates were clarified by centrifugation for 10 min at 4°C and total protein in the supernatant was determined using the Bradford assay. Two g of GST-c-Jun (1-89) was added to 50 g of total extract protein, and the reaction mixture was incubated with gentle rocking overnight at 4°C. The fusion protein complexes were washed twice with 500 l of lysis buffer and twice with 500 l of kinase buffer (25 mM Tris (pH 7.5), 5 mM ␤-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 ). Pellets were incubated in 30 l of kinase buffer with 20 M ATP and 5 Ci of ␥-32 P ATP (NEN) for 30 min at 30°C. The reactions were stopped by adding 30 l of Laemmli sample buffer and boiling and then resolved by 12% SDS-PAGE. The gels were fixed, dried, and analyzed by autoradiography.
Cell survival assays
Cells were exposed to adequate stimulus and at various times, viable cells were counted using the trypan blue dye exclusion assay. The number of total and viable cells was counted every 24 h. The percent cell viability was determined by dividing the number of viable cells by the number of total cells.
Apoptosis was analyzed by staining with a mixture of ethidium bromide (EB) and acridine orange (AO). Twenty-five l of cell suspension were mixed with 25 l of a solution containing 500 g/ml of EB and 150 g/ml of AO. Cell morphology was studied using a fluorescence microscope. Live cells fluoresce green and dead cells orange. In advanced apoptosis, nuclei take the form of bright spherical beads which are distinguishable from those in necrotic cells (spheric form).
Analysis of DNA fragmentation
Cells were harvested and DNA was prepared as previously described. 42 Briefly, 2 × 10 7 cells were washed in PBS and resuspended in 50 l of 50 mM Tris-HCl pH 8.0, 10 mM EDTA and 0.5 mg/ml proteinase K (Merck, Fontenay-sous-Bois, France). After incubation at 50°C for 1 h, 1 l of 10 mg/ml RNaseA (Roche-Boehringer, Meylan, France) was added for an additional 1 h at 37°C. The samples were mixed with 25 l of 10 mM EDTA (pH 8.0) containing 1% (w/v) low melting point agarose, 0.25% bromophenol blue and 40% sucrose at 70°C. The DNA was separated in 2% agarose gels and visualized by UV illumination after ethidium bromide staining.
TUNEL assays
Apoptotic DNA fragments were end-labeled in situ with fluorescein-12-dUTP by terminal deoxynucleotide transferase (TdT) using the Apoptosis Detection System (RocheBoehringer). Cells were analyzed on Facscan flow cytometer (Becton Dickinson) and a total of 4000 events were collected.
Results
c-Jun does not inhibit terminal differentiation of MEL cells
We have previously reported that c-Jun is a regulator of MEL erythroid differentiation. Overexpression of c-jun inhibits Leukemia hemoglobin synthesis in DMSO-induced MEL cells whereas inhibition of c-jun by antisense transcripts restores hemoglobin induction in a differentiation-resistant MEL cell line. 15 Incubation of MEL cells with an inducer-like DMSO leads to the stimulation of two major programs: one program is responsible for hemoglobin synthesis and the other for commitment to terminal maturation. 38 Several studies have indicated that the coordination of both programs is not obligatory. That is why we examined the effect of c-Jun on commitment to terminal cell division in DMSO-treated MEL cells.
During the above study, 15 we used two different MEL cell lines, the 745A cell line which does not express c-jun, and the TFP10 cell line in which c-jun expression is detected. Moreover we established c-jun sense 745A clones transfected with c-jun sense transcripts and c-jun antisense TFP10 clones. One representative c-jun sense 745A clone, 745A/c-junS, which expresses high levels of c-jun mRNA and protein was chosen for further studies. Similarly, we selected one c-jun antisense TFP10 clone, TFP10/c-junAS, which does not express c-Jun protein (Figure 1a) . To study the loss of proliferative potential after DMSO induction, cells were cultured in suspension and diluted every 2 days. When cells were cultured without DMSO, they grew logarithmically after each transfer. A similar growth was observed in 745A, TFP10 cells and both 745A/c-junS and TFP10/c-junAS clones. When cells were cultured in presence of DMSO, they progressively lost their capacity to grow in culture (Figure 1b) . A similar loss of growth arrest was observed in all the MEL cells tested, independently of c-jun expression. These findings are consistent with cell cycle analysis which showed that DMSO caused an accumulation of cells in the G0/G1 phase of the cell cycle in c-jun expressing 745A cells (745A/c-junS) and in 745A cells without c-jun expression (Figure 2a) . DMSO-or HMBAinduced differentiation of MEL cells is accompanied by an increase of the cyclin-dependent kinase inhibitor, p21, leading to proliferation arrest. 43 We asked whether the induction of differentiation by DMSO is also associated with changes of p21 in parental cells and clones (Figure 2b ). Whereas p21 protein was not detected in cells cultured without DMSO, it was induced in 745A and 745A/c-junS cells as well as in 
Spontaneous apoptosis is accelerated in c-jun expressing MEL cells before and after DMSO treatment
Given the ability of c-Jun to stimulate cell proliferation, we determined whether deregulated expression of c-jun can alter cell growth and viability in MEL cells under a variety of conditions. When cultured in the presence of 10% of serum and initiated at 10 5 cells/ml, no remarkable difference was observed in the growth kinetics of 745A and 745A/c-junS cells and of TFP10 and TFP10/c-junAS cells (Figure 3a) . In these culture conditions MEL cells exhibited similar proliferation rates for 3 days and almost similar saturation densities at 3 days of culture. However, when we studied the lifespan of MEL cells, viability decreased after 4 days of culture in c-junnegative 745A and TFP10/c-junAS cells whereas dead cells were already detected in c-jun overexpressing 745A/c-junS and TFP10 cells by 3 days (Figure 3b ). To determine whether this spontaneous cell death observed in MEL cells is apoptosis or necrosis, DNA fragmentation was analyzed by agarose gel analysis. Figure 3c shows that genomic DNA from 745A cells was degraded at 4 days of culture while DNA degradation was evident at 3 days in 745A/c-junS cells. Analysis by the TUNEL technique demonstrated that compared to 745A and TFP10/c-junAS cells, dUTP-FITC labeling was significantly increased in c-jun expressing 745A/c-junS and TFP10 cells after 4 days of culture (Figure 3d ). These results indicate that overexpression of c-jun results in increased formation of doublestranded DNA breaks and in increased spontaneous apoptosis in MEL cells.
We previously reported that DMSO-treated 745A cells exhibited delayed apoptosis compared to uninduced cells. 42 Apoptosis of MEL cells treated with DMSO was examined after staining with ethidium bromide (EB) and acridine orange (AO), quantitating the cells with morphological characteristics of apoptosis. Although DMSO treatment delayed apoptosis in both cell lines, apoptosis was detected in 745A/c-junS cells 1 day before 745A cells ( Figure 4) . These results show that overexpression of c-jun also increases spontaneous apoptosis in DMSO-induced MEL cells.
c-Jun increases drug-induced apoptosis in MEL cells
Since c-Jun induces an acceleration of spontaneous apoptosis in MEL cells, we asked whether c-Jun might regulate the induction of apoptosis by different drugs. We compared the sensitivity of c-jun expressing 745A/c-junS and TFP10 cells with that of c-jun-negative 745A and TFP10/c-junAS cells to drug-induced apoptosis. Cells were continuously treated for 6 h with anisomycin, a protein synthesis inhibitor, and the percentage of apoptotic cells was determined by staining cells with EB and AO (Figure 5a ). The loss of viability following treatment with anisomycin was faster in c-jun expressing cells. This loss of viability was due to the activation of an apoptotic process as shown by the degradation of DNA (Figure 5b ). Caspase activation is an early indicator of apoptosis. Thus, we c-Jun in terminal differentiation and apoptosis V Poindessous-Jazat et al 237
Figure 3
Cell growth and viability of untreated MEL cells in the presence of serum. Cells were seeded at 10 5 cells/ml and cultured with 10% serum. At the indicated times after growth initiation, the following parameters were determined. 
JNK activity and phosphorylation of c-Jun in drugtreated MEL cells
Recent studies have revealed that, in addition to enhanced cJun expression, phosphorylation of c-Jun by Jun N-terminal kinase (JNK) is necessary for the apoptotic responses in certain cell types. 44 Since JNK was activated by stress stimuli such as anticancer drugs, 45, 46 we determined whether JNK was activated during drug-induced apoptosis in MEL cells. JNK activity was tested in MEL cells using the GST-jun kinase assay. Anisomycin induced JNK activation 1 h after treatment in all MEL cells tested (Figure 7a 
c-Jun delays apoptosis of serum-starved in MEL cells
Since serum deprivation can trigger growth arrest and/or apoptosis depending on the particular cell line, we examined the influence of c-Jun expression on cell growth and viability in serum-deprived MEL cells. It appeared that the behavior of serum-starved MEL cells differed according to the initial cell concentration of the culture. When 745A and 745A/c-junS cells were initiated at a low cell density (5 × 10 4 cells/ml) in the serum-free medium, the cell viability remained high (85-90%) during the first 3 days of culture (Figure 9a ). Viability only decreased after 4 days of culture in both 745A and 745A/c-junS cells. However, serum-deprived 745A cells did not grow whereas 745A/c-junS cells cultured in the same conditions grew during 3 days. When cell cycle was examined at 48 h after serum deprivation, a marked accumulation of 745A cells in the S phase was observed whereas the cell cycle distribution in 745A/c-junS cells was still comparable to that of cells cultured in the presence of 10% serum (Figure 9b ). Furthermore, flow cytometric analysis revealed that 72 h after serum deprivation the proportion of sub-G1 (apoptotic) cells was no higher than 8% in either cell line, consistent with the above findings that the viability did not fall before 4 days when serum-starved MEL cells were initiated at a low cell density.
In contrast, when 745A and 745A/c-junS cells were started in the absence of serum at a high cell density (3-5 × 10 5 cells/ml), neither cell line proliferated (data not shown) and rapidly underwent apoptosis as determined by EB and AO staining ( Figure 10a ). As soon as 1 day after serum deprivation, 20% of 745A cells were apoptotic reaching 60% at 3 days. However, apoptosis was initiated later in 745A/c-junS cells and progressed between 2 (18%) and 3 days (40%). Moreover, PARP breakdown was detectable 1 day after serum deprivation in 745A cells while it appeared after 2 days in serum-deprived 745A/c-junS cells (Figure 10b ). These results indicate that apoptosis induced by serum deprivation is delayed in c-jun overexpressing MEL cells. 
Discussion
The aim of the present study was to test whether expression of c-Jun can modulate terminal differentiation and apoptosis in MEL cells. C-Jun has been believed to be involved in the regulation of MEL erythroid differentiation since it was shown that overexpression of c-Jun inhibits hemoglobin synthesis in DMSO-induced MEL cells. 15 Terminal differentiation is characterized by growth arrest and accumulation of cells in G0/G1. 47 This has been observed in MEL cells which are arrested in G0/G1 upon treatment with DMSO or HMBA. In this study we found that although MEL cells expressing c-Jun were hampered in their ability to synthetize hemoglobin with DMSO, they still accumulated in the G0/G1 phase of the cell cycle as did differentiating control cells treated with DMSO. In MEL cells, both programs of differentiation, erythroid phenotypic differentiation and growth arrest, can be separately regulated. Our data show that c-Jun interferes with erythroid differentiation without affecting terminal cell division, suggesting that it may uncouple these two programs. The role of the Cip/Kip family in cell cycle exit of terminally differentiating cells has been described in different cell types. 48 The induction of p21 Cip1 protein was recently observed during erythroid differentiation of MEL cells.
Leukemia
43 p21 was also induced in c-jun expressing cells induced with DMSO, indicating that c-Jun does not block p21 expression in differentiating MEL cells although it inhibits globin expresssion. A previous study has shown that constitutive expression of c-jun in leukemic U937 cells induces partial macrophage differentiation and accelerates terminal differentiation in response to TPA. 20 Therefore, the presence of c-Jun did not prevent the induction of terminal differentiation in two models of leukemic cells. Further studies will be necessary to clarify why c-Jun does not affect the cell cycle withdrawal in differentiating leukemic cells.
We found that c-Jun increased spontaneous and druginduced apoptosis in MEL cells. Spontaneous apoptosis occurred in densely growing cultures, increasing after 3 days of culture. C-jun overexpressing cells were more sensitive to spontaneous apoptosis than cells which did not express c-jun. These differences of sensitivity in spontaneously occurring apoptosis cannot be explained by cell density in cultures since they were observed even when cells reached similar saturation densities. We have previously reported that DMSO treatment of MEL cells induces a delay of apoptosis compared to untreated cells. However, spontaneous apoptosis observed after DMSO treatment was also accelerated in c-jun overexpressing MEL cells. Spontaneous apoptosis in cultured cells may be due to nutrient or oxygen deprivation. Activation of c-Jun has been observed during hypoxic stress, suggesting that c-Jun may modulate the cellular responses to hypoxia. 49 It is therefore possible that c-Jun accelerates the spontaneous apoptotic process induced by oxygen deprivation observed in growing MEL cultures.
Apoptosis was also induced in MEL cells by anisomycin and two anticancer drugs, daunorubicin (DNR) and etoposide. Increased drug-induced apoptosis rates were found in MEL cells overexpressing c-jun. Evidence has accumulated to implicate c-Jun as both a positive and negative modulator of distinct apoptotic pathways in many cells, including cells of hematopoietic origin. 10 It has been suggested that the function of c-Jun in the modulation of stress-induced apoptosis depends on the microenvironment and the cell type in which the stress stimulus is induced. 23 It was previously reported that expression of c-jun dominant negative mutant (TAM67) in U937 cells decreases the apoptotic effect of Ara-C and inhibits apoptosis induced by various stress agents. 50 It was also reported that the inhibition of c-jun expression by its antisense oligodeoxynucleotides blocks ceramide or heat shockinduced apoptosis in leukemic HL60 cells. 36 These findings along with our data suggest that c-Jun may positively modulate stress-induced apoptosis in leukemic cells. Future experiments will be necessary to determine whether expression of c-Jun in leukemia can influence the clinical efficacy of cytotoxic drugs.
Anisomycin, DNR and etoposide are believed to activate JNK in several types of cells. 45, 51 Although JNK has been implicated in diverse apoptotic responses of cells, 29, 30 the relationship between JNK activation and apoptosis in drug-treated cells is still poorly understood. We show here that anisomycin and DNR activate JNK early before apoptosis in all the MEL cells tested, independently of c-jun expression. Moreover, cJun is phosphorylated following anisomycin and DNR treat-
Figure 10
c-Jun delays apoptosis induced by serum deprivation in MEL cells. 745A and 745A/c-junS cells were seeded at a density of 3 × 10 5 cells/ml and cultured in serum-free medium. At the indicated times after serum deprivation, the following parameters were determined: (a) Percentage of apoptotic cells measured by staining cells with a mixture of EB and AO. All data represent the mean of triplicate cultures ± standard deviation. (b) Western blot analysis of PARP expression. ment, and the phosphorylation of c-Jun follows a time-course similar to JNK induction. These results indicate that drugs induce c-Jun phosphorylation (JNP) in c-jun overexpressing MEL cells and suggest that the increase of apoptosis in these cells may be correlated with the level of JNP. In the neuronal system, c-Jun-induced apoptosis was also correlated with JNK activity 52 and JNP. 44 However, our results show that c-junnegative MEL cells are capable of undergoing apoptosis following exposure to drugs, indicating the existence of a c-Junindependent pathway of drug-induced apoptosis. C-Jun is an important physiological substrate for JNK, but is not the only nuclear target. Since drugs induce JNK activation in MEL cells, it is possible that other substrates for JNK, such as ATF2, Elk-1, or Myc, might be involved in drug-induced apoptosis. 53 A number of cell lines become quiescent or apoptotic after serum deprivation. In MEL cells cultured at a low cell density, c-jun-negative, but not c-jun-positive cells, underwent growth arrest after serum deprivation. Apoptosis can be also induced in serum-deprived MEL cells when they are cultured at a high cell density. We found that c-Jun delayed the apoptotic process induced by serum deprivation in MEL cells. These results indicate that c-Jun may play a protective role against serum starvation in MEL cells not only by stimulating proliferation but also by decreasing apoptosis. A recent study has also shown that c-Jun may constitute a survival signal in serumdeprived A549 carcinoma cells. 54 Moreover, it has been reported that apoptosis observed in fetal livers lacking c-Jun is not restricted to hepatoblasts but also affects other cell types, such as erythroid cells. 55 Finally, Jacobs-Helber et al 56 indicated that c-Jun might protect EPO-dependent erythroid cells from apoptosis after EPO deprivation. These results, including ours, suggest that, in erythroid cells, c-Jun may provide protection from apoptosis under certain conditions. Our results demonstrate that, in MEL cells, the modulation of the apoptotic response by c-Jun depends on the nature of the apoptotic stimulus. This phenomenon might reflect the existence of different pathways of apoptosis in MEL cells. cJun is a transcription factor which is regulated by posttranslational modifications and interaction with other proteins in response to diverse stimuli. Therefore, it is possible that the regulation of c-Jun differs in drug treatment and in serum starvation of MEL cells, and that the decision for apoptotic or anti-apoptotic response is dictated by other c-Jun partners. Further studies will be necessary to understand the biochemical basis by which c-Jun exerts opposing effects on apoptosis, and to identify the c-Jun target genes that mediate these effects.
In conclusion, our data from the MEL model indicate that in spite of an inhibition of erythroid phenotypic differentiation, c-Jun does not prevents the G0/G1 accumulation in differentiating cells. Moreover, c-Jun sensitizes MEL cells to apoptotic stimuli provided by anticancer drugs such as daunorubicin or etoposide. These observations support the hypothesis that the proto-oncogene c-Jun may modulate differentiation and apoptosis in leukemic cells.
